Price movement over the last 24 hours
ADMA Biologics Inc vs Global X Cloud Computing ETF — how do they compare? ADMA Biologics Inc trades at $9.23 (market cap $2.13B), while Global X Cloud Computing ETF trades at $23.54. The key difference: Global X Cloud Computing ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | CLOU | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | Sector/Thematic |
52-Week High | $20.38 | $26.38 |
52-Week Low | $7.60 | $17.60 |
Enterprise Value | $2.20B | — |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
CLOU trades at $23.43, up 0.9% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF provides exposure to the cloud computing sector, though key valuation and profitability metrics are not disclosed in the provided data. Recent news highlights mixed performance for cloud ETFs, with some articles discussing growth potential from AI platforms while others note significant past losses in similar funds.
The outlook for CLOU hinges on broader technology and cloud computing trends, with AI adoption presenting a potential catalyst. Risks include sector volatility, competitive pressures, and regulatory developments, as seen in Europe's push for tech sovereignty. Investors should weigh the ETF's diversification benefits against the inherent uncertainties in the tech landscape.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →CLOU is a thematic ETF that invests in companies leading the cloud revolution. It targets providers of SaaS, PaaS, and IaaS, including major firms like Salesforce, Akamai, and Shopify that drive modern digital infrastructure.
Read more on CLOU →